RevolKa Ltd. Secures 210 million JPY (US$1.4 million) Series A Extension Funding to Advance Therapeutic Programs
SENDAI, Japan--(BUSINESS WIRE)--RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform called ai Protein ®, has raised 210 million JPY (US$1.4M) in Series A extension funding. This funding will advance RevolKa's drug discovery programs for rare diseases (https://www.revolka.com/news/english/collab-en/a65) and support collaborative partnering efforts. This financing round was co-led by existing investors, D3 LLC (Tomoya Nagata, Managing Partner, CEO) and TOHOKU University Venture Partners Co., Ltd. (Tetsuro Higuchi, President & CEO) with participation from DEEPCORE Inc. (Katsumasa Niki, President & CEO).
RevolKa's core technology, ai Protein ® is a robust AI-driven protein engineering technology that creates exceptionally high-performance proteins. This technology platform has already produced many successful outcomes in collaboration with partner companies.
About ai Protein ® Technology
RevolKa's proprietary ai Protein ® platform is an AI-assisted protein engineering platform. Proteins are linear polymers composed of amino acids and their derivatives, folding into a tertiary structure through internal complex atomic interactions to exhibit biological functions. The relationship between protein sequence, structure, and function remains poorly understood, limiting rational design of protein. AlphaFold developed by Google DeepMind that was awarded the Nobel prize in Chemistry in 2024 has provided an AI-driven solution to the protein sequence-to-structure relationship. ai Protein ®, in turn, addresses the protein sequence-to-function relationship. RevolKa's AI engine is trained on sequence-to-function relationship data, enabling the efficient generation of sequences of proteins with desired functions. Furthermore, ai Protein ® can simultaneously engineer multiple properties, offering a powerful and cost-effective solution for creating novel and highly functional proteins suitable for pharmaceutical and industrial applications.
About D3 LLC
D3.LLC's investment is focused on the biotech and healthcare field. Our mission is to contribute to global healthcare through not only funding promising scientific and technological seeds and business ideas (Discovery) but also working alongside entrepreneurs to create impactful products/services with sustainable business models (Development), and then realizing social implementation of the seeds and ideas (Deployment). We value investing in selected companies and providing hands-on support to them in accordance with the global standards of the biotech and healthcare VC.
About TOHOKU University Venture Partners Co., LTD.
TOHOKU University Venture Partners (THVP) is a wholly owned subsidiary of Tohoku University, established with the philosophy of creating new industries by investing in and supporting venture companies aiming to commercialize excellent technologies based on the research outcomes of Tohoku University and National universities in the Tohoku region.
After investment, THVP aims to increase corporate value and maximize shareholder value through hands-on management, business planning support, financing, and sales channel expansion support, as well as active involvement with the investee companies. THVP will also contribute to regional revitalization centered on the seven Tohoku prefectures.
About DEEPCORE Inc.
DEEPCORE is a venture capital firm dedicated to supporting startups in the fields of AI and advanced technologies, providing funding for pre-seed to early-stage companies across a broad range of industries. In addition to its investment activities, the firm operates the KERNEL community, which fosters connections among AI engineers and entrepreneurs, as well as an accelerator program aimed at helping startups expand globally. Through 'LINKS by KERNEL', the dedicated hiring and matching platform, DEEPCORE also supports career development in the startup ecosystem.
About RevolKa Ltd.
RevolKa is a venture-backed biotechnology company founded in April 2021 by academic and industry experts specializing in biotechnology and artificial intelligence. Our mission is to contribute to human well-being by creating novel proteins for therapeutics and industrial applications using our proprietary technology, ai Protein®. The name "RevolKa" is derived from the Latin word for evolution, " evolutio ' and the Ainu (an indigenous people of Japan) word for raise, ' reska '. RevolKa's headquarters and laboratories are located in Sendai, Japan. The company's investors include D3 LLC, Tohoku University Venture Partners Co., Ltd., DEEPCORE Inc., and SBI Investment Co., Ltd. For more information, visit https://www.revolka.com/en/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Dollar General Welcomes Celebrity Brands, Adding Style and Value to Every Home
DG introduces new products and collections for the home featuring renowned celebrities, designers and brands GOODLETTSVILLE, Tenn., June 05, 2025--(BUSINESS WIRE)--Dollar General (NYSE: DG) is elevating home style with the introduction of celebrity and name-brand products. The revamped 'Home Valley' section will feature collections from renowned celebrities, designers and brands, including Kathy Ireland, Betseyville®, Beverly Hills Polo Club®, Simply Belle by Simply Southern® and Nicole Miller®. Launching this summer in DG's more than 20,000 stores, ki by kathy ireland® offers a grandmillennial style collection of a dozen bedding and home items including waffle, jacquard, printed and faux fur throws, ribbed and jacquard blankets, comforter sets, quilts and sheets. Affordably priced, throws start at $12, sheet sets at $15 and 3-piece comforter sets at $35. An additional collection from the "super model turned super mogul" is planned for this fall. "Our brand philosophy of empowered living combines human rights advocacy with the support of millions of women and families who embrace our designs and products. With a shared commitment of serving the underserved, we are delighted to partner with Dollar General to offer affordable luxuries that will make a house truly feel like a home," said Kathy Ireland, chair and CEO of kathy ireland® brands. Joining the celebrity collection are Betseyville® seasonal throws and Beverly Hills Polo Club® sheets. The product selection is designed to appeal to shoppers seeking quality items at affordable prices from recognizable national brands through a treasure hunt experience. "Dollar General is committed to offering our customers a constant flow of exciting industry brands that amplify the surprise element of our non-consumable initiative," said Johanna Blankush, senior vice president, general merchandising manager at Dollar General. "We are dedicated to delivering exceptional value to our customers while staying on top of the latest trends." DG's 'Home Valley' will include hydration items from Simply Belle by Simply Southern®, Hydraflow®, Nicole Miller® and Manna® Hydration as well as Farberware® flatware. Discover ways to refresh your space by browsing Dollar General's bed, bath, kitchen, dining and home décor collections here. About Dollar General Corporation Dollar General Corporation (NYSE: DG) is proud to serve as America's neighborhood general store. Founded in 1939, Dollar General lives its mission of Serving Others every day by providing access to affordable products and services for its customers, career opportunities for its employees, and literacy and education support for its hometown communities. As of May 2, 2025, the Company's 20,582 Dollar General, DG Market, DGX and pOpshelf stores across the United States and Mi Súper Dollar General stores in Mexico provide everyday essentials including food, health and wellness products, cleaning and laundry supplies, self-care and beauty items, and seasonal décor from our high-quality private brands alongside many of the world's most trusted brands such as Coca Cola, PepsiCo/Frito-Lay, General Mills, Hershey, J.M. Smucker, Kraft, Mars, Nestlé, Procter & Gamble and Unilever. View source version on Contacts dgpr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
20 minutes ago
- Business Wire
Dollar General Welcomes Celebrity Brands, Adding Style and Value to Every Home
GOODLETTSVILLE, Tenn.--(BUSINESS WIRE)--Dollar General (NYSE: DG) is elevating home style with the introduction of celebrity and name-brand products. The revamped 'Home Valley' section will feature collections from renowned celebrities, designers and brands, including Kathy Ireland, Betseyville®, Beverly Hills Polo Club®, Simply Belle by Simply Southern® and Nicole Miller®. "With a shared commitment of serving the underserved, we are delighted to partner with Dollar General to offer affordable luxuries that will make a house truly feel like a home,' said Kathy Ireland, chair and CEO of kathy ireland® brands. Share Launching this summer in DG's more than 20,000 stores, ki by kathy ireland® offers a grandmillennial style collection of a dozen bedding and home items including waffle, jacquard, printed and faux fur throws, ribbed and jacquard blankets, comforter sets, quilts and sheets. Affordably priced, throws start at $12, sheet sets at $15 and 3-piece comforter sets at $35. An additional collection from the 'super model turned super mogul' is planned for this fall. 'Our brand philosophy of empowered living combines human rights advocacy with the support of millions of women and families who embrace our designs and products. With a shared commitment of serving the underserved, we are delighted to partner with Dollar General to offer affordable luxuries that will make a house truly feel like a home,' said Kathy Ireland, chair and CEO of kathy ireland® brands. Joining the celebrity collection are Betseyville® seasonal throws and Beverly Hills Polo Club® sheets. The product selection is designed to appeal to shoppers seeking quality items at affordable prices from recognizable national brands through a treasure hunt experience. 'Dollar General is committed to offering our customers a constant flow of exciting industry brands that amplify the surprise element of our non-consumable initiative,' said Johanna Blankush, senior vice president, general merchandising manager at Dollar General. 'We are dedicated to delivering exceptional value to our customers while staying on top of the latest trends.' DG's 'Home Valley' will include hydration items from Simply Belle by Simply Southern®, Hydraflow®, Nicole Miller® and Manna® Hydration as well as Farberware® flatware. Discover ways to refresh your space by browsing Dollar General's bed, bath, kitchen, dining and home décor collections here. About Dollar General Corporation Dollar General Corporation (NYSE: DG) is proud to serve as America's neighborhood general store. Founded in 1939, Dollar General lives its mission of Serving Others every day by providing access to affordable products and services for its customers, career opportunities for its employees, and literacy and education support for its hometown communities. As of May 2, 2025, the Company's 20,582 Dollar General, DG Market, DGX and pOpshelf stores across the United States and Mi Súper Dollar General stores in Mexico provide everyday essentials including food, health and wellness products, cleaning and laundry supplies, self-care and beauty items, and seasonal décor from our high-quality private brands alongside many of the world's most trusted brands such as Coca Cola, PepsiCo/Frito-Lay, General Mills, Hershey, J.M. Smucker, Kraft, Mars, Nestlé, Procter & Gamble and Unilever.
Yahoo
29 minutes ago
- Yahoo
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo's Canadian Portfolio
MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. ('SMPA') announced today that Knight and SMPA's affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the 'Mature Products', together with MYFEMBREE®, ORGOVYX® and vibegron, the 'Products'). For the year ended March 2025, the Products generated C$11.2 million in revenue. Under the terms of the agreements, Knight will have the exclusive rights to distribute, promote, market and sell the Products in Canada. Knight will begin commercial activities following a transition period from Sumitomo Pharma Canada. The consideration for the transaction includes an upfront amount of C$25.4 million and Knight may pay future contingent payments of up to C$15.75 million upon achieving certain sales milestones. In addition, Knight is expected to pay an estimated C$7 million for inventory to be acquired over the next eight months. 'We are pleased that Knight will continue to bring this suite of products to patients and health care providers throughout Canada,' said Tsutomu Nakagawa, Ph.D., President and Chief Executive Officer of SMPA. 'This divestiture is aligned with our long-term strategy to focus on and grow our core brands in the U.S. and to accelerate commercialization of our pipeline assets for oncology, regenerative medicine and cell therapy.' 'This transaction is another great example of our continued execution on our growth strategy of building a portfolio of innovative products,' said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc. 'MYFEMBREE®, ORGOVYX® and vibegron are highly synergistic with our current Canadian business in women's health with IMVEXXY® and BIJUVA®, as well as in urology and prostate cancer with TRELSTAR®. We look forward to expanding access to these innovative therapies to patients and healthcare providers.'Conference Call Notice Knight will host a conference call and audio webcast to discuss the acquisition on Thursday, June 5, 2025, at 8:30 am ET. Knight cordially invites all interested parties to participate in this call. Date: Thursday, June 5, 2025Time: 8:30 a.m. ETTelephone: Toll Free 1-888-699-1199 or International 1-416-945-7677Webcast: or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast. Replay: An archived replay will be available for 30 days at About MYFEMBREE® MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg tablets) was approved by Health Canada in September 2023 making it the first oral prescription treatment for both the management of heavy menstrual bleeding associated with uterine fibroids and for the management of moderate to severe pain associated with endometriosis in pre-menopausal women. According to IQVIA, sales of MYFEMBREE® in Canada were approximately C$2.9 million in 2024. About ORGOVYX® (relugolix) ORGOVYX® (relugolix 120mg tablets) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by Health Canada in October 2023 for the treatment of adult patients with advanced prostate cancer. As a GnRH antagonist, ORGOVYX® blocks the pituitary GnRH receptor, thereby reducing the release of the luteinizing and follicle-stimulating hormones, and consequently reducing the production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer. According to IQVIA, sales of ORGOVYX® in Canada were approximately C$1.2 million in 2024. About Vibegron In the U.S., vibegron 75mg tablets (tradename GEMTESA®) has been indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults since April 2021. Vibegron works by selectively targeting β3 adrenergic receptors to reduce OAB symptoms through the relaxation of the bladder detrusor muscle to increase bladder capacity. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024, as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law. About Sumitomo Pharma Sumitomo Pharma Co., Ltd., is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), Canada (Sumitomo Pharma Canada, Inc.), and Europe (Sumitomo Pharma Switzerland GmbH) focused on addressing patient needs in oncology, urology, women's health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website or follow us on LinkedIn. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. GEMTESA, MYFEMBREE and ORGOVYX are trademarks of Sumitomo Pharma Switzerland GmbH. For more information:Investor Contact for Knight Therapeutics Inc.: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website: For SMPA Thomas HillVice President, Head of Corporate Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
